# Atyr Pharma Inc. (NASDAQ:ATYR)

> aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation.

## About

aTyr is a clinical stage biotechnology company leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Their lead therapeutic candidate, efzofitimod, is in clinical development for interstitial lung disease (ILD), targeting chronic inflammation and progressive fibrosis. The company is also investigating efzofitimod in pulmonary sarcoidosis and systemic sclerosis-related ILD, with a pipeline of additional therapeutic candidates derived from their tRNA synthetase platform.

## Key facts

- **Cash position:** $68.3 million
- **Shares outstanding:** 98,043,839
- **Projects:** ["Efzofitimod NRP2 modulator | Pulmonary Sarcoidosis(1) | Phase 3 | In partnership with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILD in Japan","SSc-ILD | Phase 2 | not discovered","Other ILD (CTD-ILD; CHP) | Phase 1 | not discovered","ATYR0101 LTBP1 modulator | Fibrosis | Preclinical | not discovered","ATYR0750 FGFR4 modulator | Liver Disorders | Preclinical | not discovered","tRNA Synthetase Candidates(2) | Preclinical | Pipeline candidates in development based on additional tRNA synthetases from IP portfolio"]
- **Leadership:** Sanjay S. Shukla, M.D., M.S. (President and Chief Executive Officer, Dr. Shukla has over 15 years of experience in clinical development and medical affairs, previously serving as Chief Medical Officer at aTyr and Vice President at Novartis.), Jill M. Broadfoot (Chief Financial Officer, Ms. Broadfoot has extensive experience in finance and accounting, previously serving as CFO at Emerald Health Pharmaceuticals and Vice President at GW Pharmaceuticals.), Lisa Carey (Vice President, Clinical Operations, Ms. Carey has over 30 years of clinical operations experience, previously working at Vertex Pharmaceuticals.), Brandon Yaras (Vice President, Finance, Mr. Yaras has nearly 20 years of corporate finance experience, previously serving as Director of Finance at Arrowhead Pharmaceuticals.), Darin Lee, Ph.D. (Vice President, Technical Operations, Dr. Lee has over 20 years of biopharmaceutical industry experience, focusing on CMC and biologics development.), Danielle Campbell (Vice President, Human Resources, Ms. Campbell has a strong background in human resources, previously working at Poseida Therapeutics.), Leslie Nangle, Ph.D. (Vice President, Research, Dr. Nangle has over 20 years of research experience, focusing on extracellular tRNA synthetases.), Nancy E. Denyes (General Counsel, Ms. Denyes has extensive legal experience in corporate law, previously practicing at Cooley LLP.), Eric Benevich (Director, Mr. Benevich has over 30 years of commercial experience in the pharmaceutical industry, currently serving as Chief Commercial Officer at Neurocrine Biosciences.), Sara L. Zaknoen, M.D. (Director, Dr. Zaknoen has extensive experience in clinical drug development, previously serving as Chief Medical Officer at multiple biotech companies.), Svetlana Lucas, Ph.D. (Director, Dr. Lucas has a strong background in business development in the biotech industry, currently serving as Chief Business Officer at Scribe Therapeutics.), Jane A. Gross, Ph.D. (Director, Dr. Gross has extensive experience in research and development in biotechnology, previously serving as Chief Scientific Officer at Aptevo Therapeutics.), Timothy P. Coughlin (Director, Mr. Coughlin has a strong background in finance, previously serving as CFO at Neurocrine Biosciences.)

_Verified data last updated: 2026-09-04_

## Recent filings

- 2026-08-31 — other — [atyr_2026-08-31_09-52-42.pdf](https://chat.orbiton.app/atyr/preview/117615?documentId=117615)
- 2026-08-07 — other — [atyr_2026-08-07_19-04-16.pdf](https://chat.orbiton.app/atyr/preview/112716?documentId=112716)
- 2026-08-06 — other — [atyr_2026-08-06_13-14-37.pdf](https://chat.orbiton.app/atyr/preview/112558?documentId=112558)
- 2026-07-31 — other — [atyr_2026-07-31_19-44-28.pdf](https://chat.orbiton.app/atyr/preview/102199?documentId=102199)
- 2026-07-27 — other — [atyr_2026-07-27_19-25-27.pdf](https://chat.orbiton.app/atyr/preview/95432?documentId=95432)
- 2026-07-08 — other — [atyr_2026-07-08_10-37-30.pdf](https://chat.orbiton.app/atyr/preview/85766?documentId=85766)
- 2026-06-08 — other — [atyr_2026-06-08_19-04-31.pdf](https://chat.orbiton.app/atyr/preview/85767?documentId=85767)
- 2026-06-05 — other — [atyr_2026-06-05_13-13-06.pdf](https://chat.orbiton.app/atyr/preview/85768?documentId=85768)

## Live AI chat

- https://chat.orbiton.app/atyr/chat
- Investor website: https://atyrpharma.com/